ALLIED CORP. Financials (USD)
| Sales 2022 | 0.17 | Sales 2023 | 0.07 | Capitalization | 22.78M |
|---|---|---|---|---|---|
| Net income 2022 | -15M | Net income 2023 | -10M | EV / Sales 2022 | 289,040,315 x |
| Net Debt 2022 | 4.98M | Net Debt 2023 | 5.65M | EV / Sales 2023 | 394,366,816 x |
| P/E ratio 2022 |
-2.73
x | P/E ratio 2023 |
-2.13
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 48.93% |
More Fundamentals
* Assessed data
More news
More press releases
| Managers | Title | Age | Since |
|---|---|---|---|
Calum Hughes
CEO | Chief Executive Officer | - | - |
Ryan Maarschalk
DFI | Director of Finance/CFO | 42 | 20-03-24 |
Radka Milanova
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
James Smeeding
BRD | Director/Board Member | - | 20-05-01 |
Calum Hughes
CEO | Chief Executive Officer | - | - |
David Weinkauf
PRN | Corporate Officer/Principal | 56 | - |
Allied Corp. is an international medical cannabis production company. The Company is focused on the development of medicinal cannabis and psilocybin products for patients with conditions potentially suitable for treatment there with. Such conditions include anxiety, insomnia, anorexia, chronic pain, epilepsy, chemotherapy-induced nausea and vomiting, post-traumatic stress disorder (PTSD), Parkinsonâs disease, Tourette syndrome, irritable bowel syndrome (IBS) and spasticity associated with multiple sclerosis (MS) and spinal cord injury (SCI)1. Its wholly owned subsidiaries include AM Biosciences, Allied US Products LLC, Tactical Relief LLC, Baleno Ltd., and Allied Colombia.
Sector
Pharmaceuticals
Calendar
2024-08-08
- Q3 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +40.86% | 6.16B | |
| -16.30% | 4.49B | |
| -9.93% | 3.17B | |
| -1.58% | 3.01B | |
| -1.70% | 2.57B | |
| +37.23% | 1.8B | |
| -12.78% | 1.62B | |
| +1.02% | 1.56B | |
| -12.97% | 1.53B |
